Enhancer provides a potential target for ‘undruggable’ MYC in pediatric medulloblastoma

Efforts to develop effective therapies for MYC-amplified Group 3 medulloblastoma (G3-MB) are hindered by an incomplete understanding of how MYC expression is controlled in these tumors.

Read more: https://www.eurekalert.org/news-releases/1125370